SpringWorks Therapeutics Inc
NASDAQ:SWTX

Watchlist Manager
SpringWorks Therapeutics Inc Logo
SpringWorks Therapeutics Inc
NASDAQ:SWTX
Watchlist
Price: 46.99 USD 0.02% Market Closed
Market Cap: $3.5B

Operating Margin

-120.5%
Current
Improving
by 1 298.1%
vs 3-y average of -1 418.6%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-120.5%
=
Operating Income
$-264.7m
/
Revenue
$219.7m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-120.5%
=
Operating Income
$-264.7m
/
Revenue
$219.7m

Peer Comparison

Country Company Market Cap Operating
Margin
US
SpringWorks Therapeutics Inc
NASDAQ:SWTX
3.5B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
174.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.5B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.9B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 86% of companies in the United States of America
Percentile
14th
Based on 14 112 companies
14th percentile
-120.5%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

SpringWorks Therapeutics Inc
Glance View

Market Cap
3.5B USD
Industry
Biotechnology

SpringWorks Therapeutics Inc., a cutting-edge biopharmaceutical company, emerged from its inception as a strategic spin-out venture from the global pharmaceutical giant Pfizer. Born in 2017, the company cleverly positions itself at the forefront of the drug development process, with a keen focus on targeting rare diseases and cancer. SpringWorks leverages its robust pipeline of therapies, specifically designed to address significant unmet medical needs. Their approach revolves around the repurposing and reinvigoration of underappreciated and overlooked clinical molecules, which previously lacked the necessary backing to reach the market. This innovative approach allows SpringWorks to harness upstream R&D efforts while minimizing the typical time and resources required for de novo drug development. Earning its stripes in the field, SpringWorks generates revenue primarily through milestone and royalty agreements tied to its partnerships and co-development collaborations. Rather than relying solely on traditional sales of approved drugs, the company emphasizes strategic alliances with research institutions and pharmaceutical partners to advance its drug candidates. This co-development model extends its reach and augments the company's research capabilities, enabling SpringWorks to share risks and tap into broader resources. By nurturing innovations through collaboration, SpringWorks not only enriches its pipeline but also stands as a vanguard in transforming potential therapies into commercial realities, ultimately positioning itself as a linchpin in the orphan disease market.

SWTX Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-120.5%
=
Operating Income
$-264.7m
/
Revenue
$219.7m
What is SpringWorks Therapeutics Inc's current Operating Margin?

The current Operating Margin for SpringWorks Therapeutics Inc is -120.5%, which is above its 3-year median of -1 418.6%.

How has Operating Margin changed over time?

Over the last 1 years, SpringWorks Therapeutics Inc’s Operating Margin has increased from -6 297.3% to -120.5%. During this period, it reached a low of -6 297.3% on Dec 31, 2023 and a high of -120.5% on May 1, 2025.

Back to Top